Get started
Ensysce Biosciences, Inc.Ensysce Biosciences, Inc.Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

ENSC trade ideas

ENSC 4HR Large Bearish Channel Intacttest Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.
NASDAQ:ENSCLong
by TheCryptoChartWhisperer
ENSC SimplifiedEnsysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.
NASDAQ:ENSCLong
by TheCryptoChartWhisperer
ENSC Could still see another 5-10% trade opportunityUnfortunately I was not able to publish this in a 5 min time frame as when I made this trade that was the time frame I was using. Never the less this was a good trade today for a solid 10% move. I circled on the 2 candle stick support markers in which it had executed a double bottom which followed with volume. This gave it a good push above VWAP which is where I took the trade for a 10% run up before I sold off 9/10th of my position. I currently still hold a bit as I believe there is more to be had tomorrow still. After hours trading looked good as well touching 0.90 once again before pulling back to 0.87 for the full market close. I anticipate that a break above 0.92 with volume could open up for some more gains tomorrow. I have seen others speculate a move to 1.15-1.25 but I will have to wait and see tomorrow on where this one can go. (Not Financial Advice) Monday News - Ensysce Biosciences (ENSC) said Monday it secured $2.8 million in the fourth year of grant funding from the National Institute on Drug Abuse, or NIDA, for the development of its multi-pill abuse resistance platform. The funding will support the third part of the ongoing phase 1 clinical trial evaluating the platform. The award brings total funding from NIDA under this grant to $10.8 million, according to the statement.
NASDAQ:ENSC
by azheng2649
$ENSC entry PT 1.25-1.50 Target PTs 6-7 and higherEnsysce Biosciences shares are trading higher after Zacks Small-Cap Research set a $23 valuation on the stock. Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.
NASDAQ:ENSCLong
by BADQOMOCAWGOWLD
Bullish on Ensyce. ENSCWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NASDAQ:ENSCLong
by Rykin_Capital
$ENSC SR -133Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid BE Study of PF614 Provides Critical Step toward FDA Approval SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms designed to provide relief for those suffering with severe pain while protecting against abuse and overdose, announced today the initiation and first dosing in the Bioequivalence (BE) trial of the novel Trypsin Activated Abuse Protected (TAAP) Opioid, PF614. The BE study follows the successful completion of the multi-ascending twice daily dosing study of PF614 and will compare PF614 versus OxyContin in subjects in both fasted and fed states. This data will be critical to understand future prescribing criteria for PF614. If successful, upon completion of the BE study the Company believes that the data will support the 505(b)(2) regulatory path for clinical development of PF614, an abbreviated pathway to FDA approval. This pathway allows reference to available safety and clinical data from an approved product, and the BE data established by this study will move PF614 closer to registration. Dr. William Schmidt, Chief Medical Officer of Ensysce, commented, “We continue to be encouraged by our progress towards bringing our lead ‘next generation’ opioid to market. The completion of this study will be a critical milestone for Ensysce and a major step toward providing safer options for doctors and patients.” Commenting on the Company’s progress, Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, stated, “As we enter 2022 with strong progress across our clinical stage pipeline, we are looking forward to the data from this BE study in the second quarter of the year to position PF614 as our first commercial candidate. We believe that we have the foundation in place to realize our mission of bringing a unique pipeline of products onto the market and helping the millions who experience severe pain.” PF614 is designed as an abuse protective agent with trypsin-activated abuse protection (TAAP). TAAP chemical modification inactivates the active ingredient in Ensysce’s opioids products including PF614 and provides abuse protection, resistance to manipulation and other forms of recreational drug abuse. This study will build on the safety and pharmacokinetic results of the initial Phase 1 and 1b studies and is designed to improve the understanding of how PF614 compares to currently available commercial products. As previously announced, the clinical study is PF614-102 entitled “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics (PK) and Safety of Multiple-Ascending Oral Doses (MAD) of PF614 and the Food Effect and Bioavailability/BE of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.” The study is being conducted by Matthew Johnston, MD, PRA Health Sciences, Salt Lake City, Utah. About Ensysce Biosciences Ensysce Biosciences San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
NASDAQ:ENSCLong
by BADQOMOCAWGOWLD